Poxel

Poxel S.A.
Stock Exchange Euronext Paris
EPS
EUR0.52
Market Cap
EUR182.97 M
Shares Outstanding
25.88 M
Public Float
13.67 M

Profile

Address
259/261, avenue Jean Jaurès
Lyon Rhone-Alpes 69007
France
Employees -
Website http://www.poxel.com
Updated 07/08/2019
Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.

Financials

View All

Thomas Kuhn
Chief Executive Officer & Director
Laurent Higueret
Director